GSK to acquire Aiolos Bio in $1.4 billion deal; FogPharma’s new CEO, Mathai Mamman, unveils ‘contrarian’ plan in oncology

Taking stock of the drug industry, from the lab to the medicine chest

January 9, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug Aiolos was founded just last year and had raised a $245 million Series A round as it readied a Phase 2 trial of its asthma therapy. By Andrew Joseph STAT+ | JPM 2024: FogPharma's new CEO, Mathai Mammen, unveils 'contrarian' plan in oncology CEO Mathai Mammen plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers. By Allison DeAngelis STAT+ | Doudna institute hatches plan to 'cure hundreds of diseases' left behind by CRISPR revolution A new effort from the Nobel Prize winner's nonprofit looks to use genome editing to help patients with diseases too rare for industry to care. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser